Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Seagen Inc. Common Stock (SGEN)

Biological Products, (no Disgnostic Substances)

https://www.seagen.com

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

21823 30TH DRIVE SE, SUITE
BOTHELL, WA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/07/2001

Market Cap

43,154,776,450

Shares Outstanding

188,660,000

Weighted SO

188,662,672

Total Employees

N/A

Upcoming Earnings

02/21/2024

Similar Tickers

BMRN --.--%

ALNY --.--%

EXEL --.--%

HALO --.--%

LEGN --.--%

ZLAB --.--%

ASND --.--%

INCY --.--%

UTHR --.--%

Beta

0.3210

Last Div

0.0000

Range

126.47-228.96

Chg

-0.1600

Avg Vol

1634027

Mkt Cap

43154776450

Exch

NASDAQ

Country

US

Phone

425 527 4000

DCF Diff

14.2380

DCF

126.4320

Div Yield

0.0000

P/S

18.7601

EV Multiple

-52.2931

P/FV

16.8733

Div Yield %

0.0000

P/E

-57.3615

PEG

-5.3059

Payout

0.0000

Current Ratio

2.6726

Quick Ratio

1.9572

Cash Ratio

0.4489

DSO

100.2097

DIO

342.5548

Op Cycle

442.7645

DPO

144.9784

CCC

297.7862

Gross Margin

0.7540

Op Margin

-0.3437

Pretax Margin

-0.3212

Net Margin

-0.3261

Eff Tax Rate

-0.0153

ROA

-0.2064

ROE

-0.2806

ROCE

-0.2950

NI/EBT

1.0153

EBT/EBIT

0.9347

EBIT/Rev

-0.3437

Debt Ratio

0.0312

D/E

0.0445

LT Debt/Cap

0.0426

Total Debt/Cap

0.0426

Int Coverage

8.5878

CF/Debt

-4.7596

Equity Multi

1.4250

Rec Turnover

3.6424

Pay Turnover

2.5176

Inv Turnover

1.0655

FA Turnover

4.7171

Asset Turnover

0.6330

OCF/Share

-2.8711

FCF/Share

-3.7272

Cash/Share

6.5750

OCF/Sales

-0.2348

FCF/OCF

1.2982

CF Coverage

-4.7596

ST Coverage

0.0000

CapEx Coverage

-3.3537

Div&CapEx Cov

-3.3537

P/BV

16.8733

P/B

16.8733

P/S

18.7601

P/E

-57.3615

P/FCF

-61.5432

P/OCF

-79.6703

P/CF

-79.6703

PEG

-5.3059

P/S

18.7601

EV Multiple

-52.2931

P/FV

16.8733

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 14, 13:34 Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast The Motley Fool Dec 14, 05:34 Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years? The Motley Fool Nov 02, 10:00 This High-Yield Dividend Stock Is a Proven Wealth Creator

Revenue Product Segmentation